Phase II study of docetaxel re‐treatment in docetaxel‐pretreated castration‐resistant prostate cancer
Giuseppe Di Lorenzo(Saint Camillus International University of Health and Medical Sciences), Giacomo Cartenì(Ospedale Antonio Cardarelli), Pasquale Rescigno(Institute of Cancer Research), Vincenzo Altieri(University of Naples Federico II), Matteo Ferro(European Institute of Oncology), Carlo Buonerba(CTO Andrea Alesini), Giovannella Palmieri(Regione Campania), Sisto Perdonà(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Mimma Rizzo(University of Pavia), Florinda Scognamiglio, Riccardo Autorino(Rush University Medical Center), Sarah Scagliorini(Ospedale San Paolo), Sabino De Placido, Daniele Masala(Magna Graecia University), Alfredo Marinelli(University of Naples Federico II), Michele Aieta(Centro di Riferimento Oncologico della Basilicata), Adriana Faiella(Ospedale San Paolo), Ferdinando Riccardi(Ospedale Antonio Cardarelli)
Cited by 87
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
|The Lancet Oncology|2019|649
Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
|European Urology|2019|464
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
|Cancer Discovery|2017|422
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413